65,437 trials
COVID-19
Primary: Number of Participants With Adverse Events and Serious Adverse Events — 17; 15; 4; 6 Participants
Drug-drug Interaction · Autoimmune Diseases · Fibrotic Disease
Primary: Pharmacokinetics: Cmax of KD025 and KD025m2 in Part 1 — 1770; 2130; 227; 712 ng/mL
Lateral Canthal Lines · Crow's Feet
Primary: Number of Participants With a Response Defined as IGA-C (Investigators Global Assessment) Score ≤ 2 and a SSA-C (Subject Self-Assessment) Score ≤ 2 — 2; 3; 4; 2…
Critical Illness
Primary: Hypothetical Recruitment Rate for a Future Randomised Controlled Trial. — 30 Participants
Brain Injury · Aggression
Primary: Proportion of Participants With >2-point Increase on Neuropsychiatric Inventory - Irritability Domain Rated by Observer Day 28 — 66.3; 66.7 percentage of participants…
Cannabis-use Disorders
Primary: Number of Self-administered Puffs of Smoked Cannabis Containing Active THC Concentrations Compared to Placebo Under Controlled Laboratory Conditions — 2.00; 2.67; 3.60…
Hepatocellular Carcinoma
Primary: Participants Without Recurrence (Disease-free). — 16; 28 Participants
Hepatic Impairment · Hepatic Insufficiency · Healthy Subjects
Primary: Plasma Acalabrutinib PK Parameters — 1167; 226.1; 1161; 220.0 ng*hr/mL
Carcinoma, Non-Small-Cell Lung
Primary: Overall Survival (OS) — 21.4; 21.9 Months — p=0.74156
Diabetes Mellitus
Primary: Cohort 1: HbA1c (%) Levels at Day 180 — 8.6; 8.8 HbA1c (%) — p=0.341
Prostate Cancer
Primary: Number of Participants With Antigen-specific Interferon- Secretion as Measured by Enzyme-linked Immunospot (ELISPOT) Assay — 4 participants
Peripheral T Cell Lymphoma
Primary: Overall Response Rate (ORR) at Four Months (LYRIC Criteria) — 2; 0; 1 Participants
Cataract
Primary: Number of Emmetropic Subjects Who Are Spectacle Independent — 21 Participants
Renal Angiomyolipoma
Primary: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 40; 39; 6; 2 Participants
Dysplasia; Hip
Primary: Correct Reconstruction CLS — 138 Hips